Abstract
Introduction: The clinicopathological characteristics and efficacy of perioperative treatment of Epstein-Barr virus-associated gastric cancer (EBVaGC) were investigated. Methods: The clinicopathological characteristics and perioperative treatment outcomes of patients with EBVaGC who underwent radical gastrectomy in Tianjin Medical University Cancer Hospital from September 2016 to May 2022 were retrospectively reviewed. Disease-free survival (DFS) was analyzed, and Cox regression analysis was performed to identify risk factors. Results: The study cohort included 128 patients with EBVaGC. Histologically, 126 (98.4%) patients had adenocarcinoma and only 2 (1.6%) had adenosquamous carcinoma. In addition, 18 (14.1%) had nerve invasion and 29 (22.7%) had vascular invasion. Notably, 41 (32.0%) patients had tumors in the proximal stomach and 69 (53.9%) had no lymph node metastasis. Proficient mismatch repair was confirmed in all 104 patients with available results. Overall, 16 (12.5%) patients received neoadjuvant therapy, 81 (63.3%) received adjuvant therapy, and 10 (7.8%) received perioperative immunotherapy combined with chemotherapy. In total, 22 patients experienced disease progression or had died. The 3-year DFS rate was 75.0%. DFS was relatively poorer for patients with advanced tumor (T) stage, lymph node (N) stage, disease stage, and vascular invasion. Conclusion: EBVaGC had unique clinicopathological characteristics and prognosis. Advanced T, N, and disease stages, in addition to vascular invasion, were predictive of poorer DFS. However, the efficacy of perioperative treatment of EBVaGC remains uncertain.
References
1.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 2.
The Cancer Genome Atlas Research Network
. Comprehensive molecular characterization of gastric adenocarcinoma
. Nature
. 2014
;513
(7517
):202
–9
. 3.
Naseem
M
, Barzi
A
, Brezden-Masley
C
, Puccini
A
, Berger
MD
, Tokunaga
R
, et al. Outlooks on Epstein-Barr virus associated gastric cancer
. Cancer Treat Rev
. 2018
;66
:15
–22
. 4.
van Beek
J
, zur Hausen
A
, Klein Kranenbarg
E
, van de Velde
CJ
, Middeldorp
JM
, van den Brule
AJ
, et al. EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement
. J Clin Oncol
. 2004
;22
(4
):664
–70
. 5.
Camargo
MC
, Kim
WH
, Chiaravalli
AM
, Kim
KM
, Corvalan
AH
, Matsuo
K
, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis
. Gut
. 2014
;63
(2
):236
–43
. 6.
Sakuramoto
S
, Sasako
M
, Yamaguchi
T
, Kinoshita
T
, Fujii
M
, Nashimoto
A
, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
. N Engl J Med
. 2007
;357
(18
):1810
–20
. 7.
Bang
YJ
, Kim
YW
, Yang
HK
, Chung
HC
, Park
YK
, Lee
KH
, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
. Lancet
. 2012
;379
(9813
):315
–21
. 8.
Al-Batran
S-E
, Homann
N
, Pauligk
C
, Goetze
TO
, Meiler
J
, Kasper
S
, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
. Lancet
. 2019
;393
(10184
):1948
–57
. 9.
Zhang
X
, Liang
H
, Li
Z
, Xue
Y
, Wang
Y
, Zhou
Z
, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
. Lancet Oncol
. 2021
;22
(8
):1081
–92
. 10.
Cristescu
R
, Lee
J
, Nebozhyn
M
, Kim
KM
, Ting
JC
, Wong
SS
, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
. Nat Med
. 2015
;21
(5
):449
–56
. 11.
Sohn
BH
, Hwang
JE
, Jang
HJ
, Lee
HS
, Oh
SC
, Shim
JJ
, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome Atlas project
. Clin Cancer Res
. 2017
;23
(15
):4441
–9
. 12.
Baek
DW
, Kang
BW
, Kim
JG
. The predictive value of epstein-barr virus-positivity in patients undergoing gastrectomy followed by adjuvant chemotherapy
. Chonnam Med J
. 2018
;54
(3
):173
–7
. 13.
Saito
M
, Kono
K
. Landscape of EBV-positive gastric cancer
. Gastric Cancer
. 2021
;24
(5
):983
–9
. 14.
Murphy
G
, Pfeiffer
R
, Camargo
MC
, Rabkin
CS
. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location
. Gastroenterology
. 2009
;137
(3
):824
–33
. 15.
Park
JH
, Kim
EK
, Kim
YH
, Kim
JH
, Bae
YS
, Lee
YC
, et al. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer
. Gastric Cancer
. 2016
;19
(4
):1041
–51
. 16.
Zhang
YW
, Zhao
XX
, Tan
C
, Zhang
ZG
, Jiang
Y
, Chen
JN
, et al. Epstein-Barr virus latent membrane protein 2A suppresses the expression of HER2 via a pathway involving TWIST and YB-1 in Epstein-Barr virus-associated gastric carcinomas
. Oncotarget
. 2015
;6
(1
):207
–20
. 17.
Liu
Y
, Zang
FL
, Qiu
ZQ
, Guo
YH
, Luo
Y
, Sun
L
, et al. Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients
. Zhonghua Wei Chang Wai Ke Za Zhi
. 2021
;24
(5
):440
–8
. 18.
Xie
T
, Peng
Z
, Liu
Y
, Zhang
Z
, Zhang
X
, Li
J
, et al. Clinicopathological characteristics and response to chemotherapy in treatment-naive Epstein-Barr virus associated gastric cancer: a retrospective study
. Front Oncol
. 2021
;11
:611676
. 19.
Derks
S
, Liao
X
, Chiaravalli
AM
, Xu
X
, Camargo
MC
, Solcia
E
, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
. Oncotarget
. 2016
;7
(22
):32925
–32
. 20.
Koh
J
, Ock
CY
, Kim
JW
, Nam
SK
, Kwak
Y
, Yun
S
, et al. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients
. Oncotarget
. 2017
;8
(16
):26356
–67
. 21.
Saito
R
, Abe
H
, Kunita
A
, Yamashita
H
, Seto
Y
, Fukayama
M
. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications
. Mod Pathol
. 2017
;30
(3
):427
–39
. 22.
Bai
Y
, Xie
T
, Wang
Z
, Tong
S
, Zhao
X
, Zhao
F
, et al. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer
. J Immunother Cancer
. 2022
;10
(3
):e004080
. 23.
Lei
X
, Wang
Y
, Shan
F
, Li
S
, Jia
Y
, Miao
R
, et al. Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive
. J Chin Med Assoc
. 2023
;86
(8
):717
–24
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
